Overview

Phase 1 Bioavailability Study of SYR-322MET

Status:
Completed

Trial end date:
2016-04-01

Target enrollment:

Participant gender:

Summary

The purpose of this study is to determine the relative bioavailability of alogliptin 12.5 milligram (mg) and immediate-release metformin 1000 mg when administered as individual tablets and as a fixed-dose combination (FDC) product.

Phase:

Phase 1

Details

Lead Sponsor:

Takeda

Treatments:

Alogliptin
Metformin